Skip to main content
SpringerLink
Log in

The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML — A comparative morphometric study on sequential trephine biopsies

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

To evaluate treatment-related changes of the reticulin stain-measured fibrosis in Ph1+-CML, a clinicopathological study was performed on sequential trephine biopsies of the bone marrow following either interferon (IFN) or busulfan (BU) monotherapy. Using the monoclonal antibody CD61 for the identification of megakaryopoiesis and Gomori's silver impregnation method, number of megakaryocytes and density of argyrophilic (reticulin and collagen) fibers were determined by morphometry. We studied specimens from 26 patients with IFN-alpha 2b (including nine patients with additional IFN gamma) therapy and from 23 patients who had received BU. In both groups, repeated bone marrow biopsies (total 125) revealed a significant increase in the fiber content, as well as in the number of megakaryocytes during treatment. To assess the dynamics of myelofibrosis more precisely, computation of differences in the degree of fiber density between the first and last examination was carried out. Regarding the considerable variations in the biopsy intervals, a so-called myelofibrosis progression index (MPI) was calculated. Following this rationale, we were able to demonstrate that, in comparison to the BU-group, speed of progression of bone marrow fibrosis was significantly increased in CML patients treated with IFN. Preliminary statistical analysis indicated a relationship between myelofibrosis on admission, which was always associated with increased growth of megakaryocytes, and the MPI with survival. Even when these parameters were regarded, prognosis was significantly more favorable in the IFN-treated patients. The failure of IFN and BU to inhibit the evolution of myelofibrosis may be related to several conversely acting pathomechanisms. Among others, the inability of both therapeutic agents to reduce the number of megakaryocytes more effectively should be taken into consideration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bardawil RG, Grovers C, Ratain MJ, Golomb HM, Vardiman JW (1986) Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2-interferon for hairy cell leukemia. Am J Clin Pathol 85:194–201

    PubMed  Google Scholar 

  2. Barosi G, Liberato LN, Costa A, Ascari E (1989) Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 58:271–274

    PubMed  Google Scholar 

  3. Bauermeister DE (1971) Quantitation of bone marrow reticulin: a normal range. Am J Clin Pathol 56:24–31

    PubMed  Google Scholar 

  4. Bernabei P, Arcangeli A, Casini M, Grossi A, Padovani R, Rossi Ferrini P (1986) Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Br J Haematol 63:353–357

    PubMed  Google Scholar 

  5. Bishop JB, Wassom JS (1986) Toxicological review of busulfan (Myleran). Mutat Res 168:15–45

    PubMed  Google Scholar 

  6. Buhr T, Choritz H, Georgii A (1992) The impact of megakaryocyte proliferation for the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukemia. Virchows Arch [A] 420:473–478

    Google Scholar 

  7. Buhr T, Georgii A, Choritz H (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover classification. Pathol Res Pract 189:121–132

    PubMed  Google Scholar 

  8. Castro-Malaspina H (1984) Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: Berk P, Castro-Malaspina H, Wasserman L (eds) Myelofibrosis and the biology of connective tissue. Liss, New York, pp 427–454

    Google Scholar 

  9. Clough V, Geary CG, Hashimi K, Davson G, Knowlson T (1979) Myelofibrosis in chronic granulocytic leukaemia. Br J Haematol 42:515–526

    PubMed  Google Scholar 

  10. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ (1987) The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 59:1739–1743

    Google Scholar 

  11. Dowding C, Gordon M, Guo AP, Maison D, Osterholz J, Siczkowski M, Goldman J (1993) Potential mechanisms of action of interferon-alpha in CML. Leuk Lymphoma 11:185–191

    PubMed  Google Scholar 

  12. Fohlmeister I, Klein H, Thiele J, Wienhold S, Fischer R (1988) Morphometric assessment of bone marrow fiber content in acute non-lymphatic leukemia at presentation. Anal Quant Cytol Histol 10:110–114

    PubMed  Google Scholar 

  13. Galvani DW, Cawley JC (1989) Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br J Haematol 73:475–479

    PubMed  Google Scholar 

  14. Galvani DW, Cawley JC (1990) The effects of interferon on human long-term bone marrow culture. Leukem Res 14:525–531

    Google Scholar 

  15. Gatter KC, Cordell JL, Turley A, Heryet A, Kiefer N, Anstee DJ, Mason D (1988) The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology 13:257–267

    PubMed  Google Scholar 

  16. Georgii A, Vykoupil KF, Buhr T, Choritz H, Doehler U, Kaloutsi V, Werner M (1990) Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract 186:3–27

    PubMed  Google Scholar 

  17. Gralnick HR, Harbor J, Vogel C (1971) Myelofibrosis in chronic granulocytic leukemia. Blood 37:152–162

    PubMed  Google Scholar 

  18. Greenberg BR, Woo L, Veomett IC, Payne CM, Ahmann FR (1987) Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br J Haematol 66:487–490

    PubMed  Google Scholar 

  19. Hasselbalch H (1988) Interferon in myelofibrosis. Lancet 1:355

    Google Scholar 

  20. Hasselbalch H, Lisse I (1991) A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. Eur J Haematol 46:285–289

    PubMed  Google Scholar 

  21. Hasselbalch H, Braide I, Lisse I, Röckert L, Swolin B, Carneskog J, Hagberg H, Hippe E, Jensen MK, Lundin P, Malm C, Nielsen B, Rödjer S, Westin J, Zador G (1988) Recombinant interferon-alpha-2b treatment of hairy cell leukaemia: experience with a low-dose schedule. Eur J Haematol 41:438–444

    PubMed  Google Scholar 

  22. Islam A, Catovsky D, Goldmann JM, Galton DAG (1981) Histological study of bone marrow in chronic granulocytic leukaemia in blast transformation. II. Bone marrow fibre content before and after autografting. Histopathology 5:491–498

    PubMed  Google Scholar 

  23. Islam A, Catovsky D, Goldman JM, Galton DAG (1984) Bone marrow fibre content in acute myeloid leukaemia before and after treatment. J Clin Pathol 37:1259–1263

    PubMed  Google Scholar 

  24. Jamshidi K, Swaim WR (1971) Bone marrow biopsy with unaltered architecture: a new biopsy device. J Lab Clin Med 77:335–342

    PubMed  Google Scholar 

  25. Kantarjian HM, Talpaz M (1993) Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M.D. Anderson Cancer Center. Leuk Lymphoma 11:169–174

    PubMed  Google Scholar 

  26. Katoh O, Kimura A, Kuramoto A (1988) Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am J Hematol 27:276–280

    PubMed  Google Scholar 

  27. Katoh O, Kimura A, Itoh T, Kuramoto A (1990) Platelet-derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 35:145–150

    PubMed  Google Scholar 

  28. Kimura A, Katoh O, Kuramoto A (1988) Effects of plateletderived growth factor, epidermal growth factor and transforming growth factor-β on the growth of human marrow fibroblasts. Br J Haematol 69:9–12

    PubMed  Google Scholar 

  29. Kloke O, Wandl U, Opalka B, Moritz T, Nagel-Hiemke M, Franz T, Hirche H, Seeber S, Niederle N (1992) A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukemia. Eur J Haematol 48:93–98

    PubMed  Google Scholar 

  30. Kloke O, Niederle N, Qui JY, Wandl U, Moritz T, Nagel-Hiemke M, Hawig I, Opalka B, Seeber S, Becher R (1993) Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 83:399–403

    PubMed  Google Scholar 

  31. Laughlin M, Islam A, Barcos M, Meade P, Ozer H, Gavigan M, Henderson E, Han T (1988) Effect of alpha-interferon therapy on bone marrow fibrosis in hairy cell leukemia. Blood 72:936–939

    PubMed  Google Scholar 

  32. Lazzarino M, Morra E, Castello A, Inverardi D, Coci A, Pagnucco G, Magrini U, Zei G, Bernasconi C (1986) Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance. Br J Haematol 64:227–240

    PubMed  Google Scholar 

  33. Löfvenberg E, Wahlin A, Roos G, Öst A (1990) Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 44:33–38

    PubMed  Google Scholar 

  34. MacCarthy DM (1985) Fibrosis of the bone marrow: content and causes. Br J Haematol 59:1–7

    PubMed  Google Scholar 

  35. Manoharan A, Pitney WR (1984) Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 33:453–459

    PubMed  Google Scholar 

  36. Martyre MC (1991) Platelet PDGF and TGF-β levels in myeloproliferative disorders. Leuk Lymphoma 6:1–6

    Google Scholar 

  37. Mehta AB, Baughan AS, Catovsky D, Goldman JM, Johnsons SA, Galton DAG (1983) Reversal of bone marrow fibrosis in acute megakaryoblastic leukaemia after remission induction and consolidation chemotherapy followed by bone marrow transplantation. Br J Haematol 53:445–449

    PubMed  Google Scholar 

  38. Morra E, Lazzarino M, Alimena G, Liberati AM, Grignani F, Mandelli F, Bernasconi C (1992) The role of interferon in the treatment of chronic myelogenous leukemia: results and prospects. Leuk Lymphoma 6:305–315

    Google Scholar 

  39. Naeim F, Jacobs AD (1985) Bone marrow changes in patients with hairy cell leukemia treated by recombinant alpha 2-interferon. Hum Pathol 16:1200–1205

    PubMed  Google Scholar 

  40. Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B (1993) Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymphoma 9:111–119

    PubMed  Google Scholar 

  41. Opalka B, Wandl UB, Becher R, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N (1991) Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferonα-2b alone or in combination with interferonγ. Blood 78:2188–2193

    PubMed  Google Scholar 

  42. Parmeggiani L, Ferrant A, Rodhain J, Michaux JL, Sokal G (1987) Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 39:228–232

    PubMed  Google Scholar 

  43. Stella CC, Cazzola M (1988) Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. Haematologica (Pavia) 73:225–237

    Google Scholar 

  44. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280–1288

    PubMed  Google Scholar 

  45. Thiele J, Simon KG, Fischer R, Zankovich R (1988) Followup studies with sequential bone marrow biopsies in chronic myeloid leukaemia and so-called primary (idiopathic) osteomyelofibrosis. Evolution of histopathological lesions and clinical course in 40 patients. Pathol Res Pract 183:434–445

    PubMed  Google Scholar 

  46. Thiele J, Langohr J, Skorupka M, Fischer R (1990) Reticulin fibre content of bone marrow infiltrates of malignant nonHodgkin's lymphomas (B-cell type, low malignancy) — a morphometric evaluation before and after therapy. Virchows Archiv [A] 417:485–492

    Google Scholar 

  47. Thiele J, Wienhold S, Zankovich R, Fischer R (1990) A histomorphometrical analysis of trephine biopsies of bone marrow from 65 patients with chronic myeloid leukemia — classification of patients into subgroups with different survival patterns. Anal Quant Cytol Histol 12:103–116

    PubMed  Google Scholar 

  48. Thiele J, Grashof K, Fischer R (1991) Follow-up study on bone marrow reticulin fibrosis in AML. Anal Cell Pathol 3:225–231

    PubMed  Google Scholar 

  49. Thiele J, Kvasnicka HM, Zankovich R, Fischer R, Diehl V (1991) Parameters of predictive value in chronic myeloid leukemia — the prognostic impact of histopathological variables in a multivariate regression analysis. Leuk Lymphoma 4:63–74

    Google Scholar 

  50. Thiele J, Kvasnicka HM, Titius BR, Parpert U, Nebel R, Zankovich R, Dienemann D, Stein H, Diehl V, Fischer R (1993) Histological features of prognostic significance in CML — an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann Hematol 66:291–302

    PubMed  Google Scholar 

  51. Wandl UB, Bützler R, Niederle N, Kloke O, Mengelkoch B, Becher R, Seeber S, Opalka B (1994) Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing longterm interferon treatment. Leukemia 8:776–779

    PubMed  Google Scholar 

  52. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P (1992) Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 80:184–188

    PubMed  Google Scholar 

  53. Yonekura S, Nagao T, Arimori S (1985) Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia. Br J Haematol 61:93–99

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, University of Cologne, Joseph-Stelzmann-Str. 9, D-50924, Cologne, Germany

    J. Thiele, H. M. Kvasnicka, T. K. Zirbes, M. Schmidt, J. Dammasch, B. R. Meuter & R. Fischer

  2. First Clinic of Medicine, University of Cologne, Cologne, Germany

    V. Diehl

  3. Department of Oncology and Hematology, Klinikum Leverkusen, Leverkusen, Germany

    N. Niederle

  4. Institute of Pathology, West German Cancer Center, University of Essen, Essen, Germany

    L. -D. Leder

  5. Department of Internal Medicine (Cancer Research), West Germany Cancer Center, University of Essen, Essen, Germany

    O. Kloke

Authors
  1. J. Thiele
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. M. Kvasnicka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. K. Zirbes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Dammasch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. R. Meuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. -D. Leder
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. O. Kloke
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V. Diehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by a grant from theDeutsche Forschungsgemeinschaft (DFG — Th 390/1-3)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thiele, J., Kvasnicka, H.M., Niederle, N. et al. The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML — A comparative morphometric study on sequential trephine biopsies. Ann Hematol 70, 121–128 (1995). https://doi.org/10.1007/BF01682031

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01682031

Key words

Search

Navigation